NephroPlus FY26 Revenue Soars 32% to ₹998.8 Cr, Profit Jumps 74%

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
NephroPlus FY26 Revenue Soars 32% to ₹998.8 Cr, Profit Jumps 74%
Overview

NephroPlus (Nephrocare Health Services) announced a strong fiscal year 2026 with revenue climbing 32.2% to ₹998.8 crore and adjusted profit after tax jumping 74.6% to ₹128.3 crore. The company’s international growth, particularly in new markets, contributed significantly to these results.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

NephroPlus, also known as Nephrocare Health Services Ltd, has reported its financial performance for the fiscal year ending March 31, 2026. The company achieved a notable 32.2% year-over-year revenue increase, reaching ₹998.8 crore. Profitability also saw substantial improvement, with Adjusted Profit After Tax (PAT) rising by 74.6% to ₹128.3 crore.

Strong Growth Momentum

This performance highlights NephroPlus's robust business expansion and effective operational strategies. The significant rise in PAT indicates enhanced profitability and efficiency within the company's healthcare services segment.

Strategic Expansion Drives Results

NephroPlus has actively pursued growth by expanding its dialysis services both within India and internationally. The company aims to replicate its successful business model in global markets, with ongoing expansion efforts in countries such as the Philippines, Uzbekistan, and Saudi Arabia.

Investor Confidence and Future Outlook

The company's strong financial results are expected to bolster investor confidence. Future growth is anticipated from continued international ventures, supported by investments in technology and operational enhancements designed to improve service delivery and patient care.

Navigating Expansion Risks

Despite the positive growth, NephroPlus faces challenges associated with rapid global expansion. These include adapting to potential regulatory changes in new markets and managing increasing operational costs across diverse geographies. Sustaining profitability will depend on effective cost management.

Key Performance Metrics for FY26

  • Revenue: ₹998.8 crore (up 32.2% year-over-year)
  • Adjusted EBITDA: ₹238.1 crore (up 37.6% year-over-year)
  • Adjusted Profit After Tax (PAT): ₹128.3 crore (up 74.6% year-over-year)
  • Guests Served: 36,981 (up 11.8% year-over-year)
  • Treatments Performed: 38,44,658 (up 16.6% year-over-year)
  • Annualized Adjusted ROCE: 22.8% (compared to 19.9% in FY25)

What to Watch Next

Investors will closely monitor the company's progress in its international markets and its ability to manage operational expenses. Future financial reports will be key to assessing the sustainability of its current growth trajectory.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.